{
    "id": "97a53650-f9e2-432d-a5bc-c2629021e056",
    "indications": "WAKIX is indicated for the:\n                  \n                     treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.\n                     \n                        treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.",
    "contraindications": "See Full Prescribing Information for complete dosage instructions ( 2.1 , 2.2 ) Administer orally once daily in the morning upon wakening ( 2.1 , 2.2 ) Dosage Recommendations: Adults: EDS or Cataplexy ( 2.1 ) Week 1 Initiate with a dosage of 8.9 mg once daily Week 2 Increase dosage to 17.8 mg once daily Week 3 May increase to the maximum recommended dosage of 35.6 mg once daily Pediatric Patients (6 years and older): EDS ( 2.2 ) Week 1 Initiate with a dosage of 4.45 mg once daily Week 2 Increase dosage to 8.9 mg once daily Week 3 Increase dosage to 17.8 mg once daily, the maximum recommended dosage for patients weighing <40 kg Week 4 For patients weighing ≥40 kg, may increase to the maximum recommended dosage of 35.6 mg once daily Hepatic impairment ( 2.3 , 8.6 , 12.3 ): Moderate hepatic impairment (Child-Pugh Class B): Adults: Initial dosage is 8.9 mg once daily. Titrate to a maximum dosage of 17.8 mg once daily after 14 days Pediatric Patients: Initial dosage is 4.45 mg once daily. Titrate to 8.9 mg once daily after 14 days; for patients weighing ≥40 kg, may increase to 17.8 mg once daily after another 14 days Renal impairment (eGFR less than 60 mL/minute/1.73 m 2 ) ( 2.4 , 8.7 , 12.3 ): Adults: Initial dosage is 8.9 mg once daily. Titrate to a maximum dosage of 17.8 mg once daily after 7 days Pediatric Patients: Initial dosage is 4.45 mg once daily. Titrate to 8.9 mg once daily after 7 days; for patients weighing ≥40 kg, may increase to 17.8 mg once daily after another 7 days End-stage renal disease (ESRD): Not recommended Poor Metabolizers of CYP2D6 ( 2.6 ): Adults: Maximum recommended dosage is 17.8 mg once daily Pediatric Patients: Maximum recommended dosage is 8.9 mg once daily for patients weighing <40 kg and 17.8 mg for patients weighing ≥40 kg",
    "warningsAndPrecautions": "WAKIX (pitolisant) tablets are available as:\n                        4.45 mg: white, round, biconvex film-coated tablet, 3.7 mm diameter, marked with “S” on one side and plain on the other side.\n                        NDC 72028-045-03 – Bottles of 30\n                        17.8 mg: white, round, biconvex film-coated tablet, 7.5 mm diameter, marked with “H” on one side and plain on the other side.\n                        NDC 72028-178-03 – Bottles of 30",
    "adverseReactions": "WAKIX is contraindicated in patients with:\n                  \n                     known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported in patients treated with WAKIX [see Adverse Reactions (6.2)].\n                     severe hepatic impairment. WAKIX is extensively metabolized by the liver and there is a significant increase in WAKIX exposure in patients with moderate hepatic impairment [see Use in Specific Populations (8.6)].",
    "ingredients": [
        {
            "name": "PITOLISANT HYDROCHLORIDE",
            "code": "YV33CH63HI"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "organization": "Harmony Biosciences, LLC",
    "name": "Wakix",
    "effectiveTime": "20250513"
}